- 7.2.2025
- News
Why Veterans With PTSD Are Turning to Psychedelics
Veterans are increasingly exploring psychedelic treatments—like ketamine, ayahuasca, psilocybin, MDMA, and ibogaine—to heal from PTSD. These therapies tend to be used in guided, clinically-informed settings, with some programs even including spouses for shared healing. Although ibogaine remains illegal in the U.S., many veterans are traveling abroad, driven by promising early results

- 7.2.2025
- News
‘Psychedelics and the Texas Trip’ explores science & history behind state-funded research initiative
Texas recently approved $50 million in public funding, matched privately, to study ibogaine—a plant-derived psychedelic—as a potential treatment for PTSD, TBI, addiction, and related conditions. The initiative is facilitated through a public–private partnership and includes protections to ensure future therapy revenues fund veterans’ programs

- 7.2.2025
- News
Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing
Texas is the first state to fund clinical trials of ibogaine, investing $50 million in public funds to explore its potential for treating PTSD, addiction, and TBI—with future revenues supporting veterans’ programs.

- 7.2.2025
- News
Texas governor signs bill allocating up to $100 million in funding for psychedelics research
Texas has passed a landmark bill dedicating up to $100 million—half from public funds—to study ibogaine for conditions like PTSD, TBI, and addiction. A portion of future revenue will directly support veterans’ programs, marking a major step toward expanding access to psychedelic-assisted therapies.